EFSA responds to a health claim application from collagen protein firm Gelita.
“Wrinkle reduction” and “higher elasticity” do not qualify as health functions and thus do not merit health claims, says the European Food Safety Authority (EFSA; Parma, Italy). EFSA published this opinion on June 20, in response to an Article 13.5 health claim application from collagen protein ingredients specialist Gelita (Eberbach, Germany) for the firm’s Verisol collagen peptide ingredient.
Gelita’s application proposed a health claim effect of “maintenance of skin health, as indicated by an increased skin elasticity and a reduction of wrinkles volume,” according to EFSA documents. EFSA said it informed Gelita in 2012 “that a change in skin structure contributing to the maintenance (i.e. reduced loss) of skin function might be considered a beneficial physiological effect provided that there is evidence that such changes in skin structure lead to changes in skin function.” EFSA also added, however, that basic maintenance of skin health-such as normal structure, hydration, elasticity, or appearance of the skin, or a decrease in wrinkles-might not be classified as a change in skin function.
According to EFSA, Gelita’s evidence did not demonstrate statistically significant effects of what EFSA considers “skin function.” The company’s evidence included two unpublished, placebo-controlled, randomized human studies, one unpublished animal study, and one unpublished in vitro study.
EFSA did not negate the fact that the studies did show a significant improvement in skin elasticity and wrinkle reduction (with a daily dose of 2.5 g); however, EFSA still stated, after reviewing the evidence, that it does not consider elasticity and wrinkle reduction “skin functions.”
Gelita says that even though companies can’t use an EFSA health claim implying a change in skin function, that the company’s evidence would still be strong enough to support general beauty claims of “increased skin elasticity” and “reduced wrinkles. “We believe that a beauty claim that does not suggest or imply that a relationship between the food and health does exist may be used if supported by strong and relevant scientific studies,” Gelita stated in a press release.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
U.S. Hemp Authority announces Adult Use Hemp Product Certification Program
April 15th 2024The U.S. Hemp Authority (USHA) has announced the launch of its Adult Use Hemp Product Certification Program in an effort to “reshape public policy around hemp, and to build confidence among retailers and consumers alike.”